-
1.发明公开公开(公告)号：US20240197985A1
公开(公告)日：2024-06-20
申请号：US18528111
申请日：2023-12-04
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI
CPC classification number: A61M5/14248 , A61M5/172 , A61M2205/582
Abstract: Disclosed are techniques, devices and systems that implement and utilize a voice control application and sound chip circuitry to control operation of a wearable drug delivery device. In addition, a wearable drug delivery device equipped with the sound chip circuitry may be operable to play audio clips that may include content for assisting a user with an initial set up of the wearable drug delivery device, providing messages of encouragement, lullabies for pediatric users, and the like. In addition, the voice control application enables users to control delivery of liquid drugs via a wearable drug delivery device hands-free using voice commands and voice confirmations of actions to be taken by an automated insulin delivery application.
-
公开(公告)号：US20240312587A1
公开(公告)日：2024-09-19
申请号：US18601141
申请日：2024-03-11
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI
Abstract: A system for utilizing wireless communication tags with wearable medical devices is presented. The system includes a user device. The system includes at least a wireless communication tag. The at least a wireless communication tag is configured to communicate physiology affecting information to the user device. The user device is configured to modify a mode of operation of a wearable medical device, such as a wearable injection device, as a function of the physiology affecting information.
-
公开(公告)号：US20230032033A1
公开(公告)日：2023-02-02
申请号：US17812817
申请日：2022-07-15
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI
IPC: A61M5/172
Abstract: Disclosed are an automatic medication delivery system includes a stress detection and response algorithm or application that may operate in cooperation with a medication delivery algorithm or application. Execution of the instructions of the stress detection and response application causes a processor to obtain a respective measurement value related to a physiological condition of a user from one or more sensors. The obtained respective measurement values are evaluated against a respective threshold measurement value. The processor determines, based on the evaluation of the obtained respective measurement values, a degree of stress the user is experiencing. In response to the determination of the degree of stress the user is experiencing, the processor may modify an imminent dosage of a liquid drug to be delivered, a time of delivery of the imminent dosage, or both. A dosage of the liquid drug may be expelled based on the modifying.
-
公开(公告)号：US20220361812A1
公开(公告)日：2022-11-17
申请号：US17736380
申请日：2022-05-04
Applicant: Insulet Corporation
Inventor： Rangarajan NARAYANASWAMI , Yibin ZHENG , Jay JANTZ , Joon Bok LEE
Abstract: The disclosed embodiments are directed to systems and methods for providing optimized, individualized bolus dosing of insulin based on a macronutrient profile of meals ingested by the patient. Optimized bolus dosing may be provided by varying the overall quantity of insulin delivered in the post-prandial window, as well as the split between a portion of the insulin delivered immediately after the meal and a portion of the insulin delivered later in the post-prandial window, based on an analysis of the macronutrient profile of the meal and the behavior of the blood glucose trace of the patient from past meals.
-
公开(公告)号：US20240424212A1
公开(公告)日：2024-12-26
申请号：US18824363
申请日：2024-09-04
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI , Yibin ZHENG , Mert SEVIL , William WHITELEY , Saeed SALAVATI , Sam CARL
IPC: A61M5/172
Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.
-
Patent Agency Ranking
6.发明公开公开(公告)号：US20240226433A1
公开(公告)日：2024-07-11
申请号：US18390338
申请日：2023-12-20
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI , Yibin ZHENG , Mert SEVIL , William WHITELEY , Saeed SALAVATI , Sam CARL
IPC: A61M5/172
CPC classification number: A61M5/1723 , A61M2005/1726 , A61M2205/505 , A61M2230/201
Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.
-
公开(公告)号：US20230347053A1
公开(公告)日：2023-11-02
申请号：US18306061
申请日：2023-04-24
Applicant: Insulet Corporation
Inventor： David NAZZARO , Rangarajan NARAYANASWAMI
CPC classification number: A61M5/1723 , A61M5/142 , A61M2202/0486
Abstract: The exemplary embodiments may detect the changed ambient air pressure and may adjust settings for the medicament delivery device to compensate for the changed ambient air pressure. The exemplary embodiments may detect the changed ambient air pressure and may adjust settings for the medicament delivery device to compensate for the changed ambient air pressure. Based on the detection of these events, the medicament delivery device may be switched into a flight mode. In the flight mode, medicament boluses may be reduced to nominal dosages, basal delivery rates may be modified and sample periods for sensors, like glucose monitors, may be shortened to sample sensor values more frequently. The exemplary embodiments may prohibit delivery of medicament during times of changing ambient air pressure to avoid over-delivering or under-delivering the medicament due to the ambient air pressure level.
-
8.发明申请公开(公告)号：US20230001089A1
公开(公告)日：2023-01-05
申请号：US17848675
申请日：2022-06-24
Applicant: INSULET CORPORATION
Inventor： Rangarajan NARAYANASWAMI
Abstract: Exemplary embodiments account for differing needs of a user over the menstrual cycle of the user to better control the blood glucose concentration of the user. The exemplary embodiments may be realized in control systems for medicament delivery devices that deliver medicaments, such as medicaments that regulate blood glucose concentration levels. Examples of such medicaments that regulate blood glucose concentration levels include insulin, glucagon, and glucagon peptide-1 (GLP-1) agonists. The exemplary embodiments are able to better tailor the dosages of the medicament delivered to the user with the medicament delivery device to reduce the risk of hyperglycemia and hypoglycemia and help reduce blood glucose concentration excursions.
-
公开(公告)号：US20220062548A1
公开(公告)日：2022-03-03
申请号：US17406209
申请日：2021-08-19
Applicant: Insulet Corporation
Inventor： Yibin ZHENG , Rangarajan NARAYANASWAMI , Joon Bok LEE
Abstract: Disclosed are systems, devices, methods and computer-readable medium products that compensate for consumption of a meal by providing a reduced-constraint meal bolus dosage. The reduced-constraint meal bolus dosage is determined using post-prandial safety constraints that are reduced based on an indication that a meal has been consumed. The post-prandial safety constraints are intended to protect users from overdelivering or underdelivering insulin to the user. The determinations may be performed by a control algorithm-based drug delivery system that enables automatic delivery of a drug, such as insulin or the like.
-
公开(公告)号：US20210128831A1
公开(公告)日：2021-05-06
申请号：US17085344
申请日：2020-10-30
Applicant: Insulet Corporation
Inventor： Ashutosh ZADE , Joon Bok LEE , Yibin ZHENG , Rangarajan NARAYANASWAMI , David NAZZARO , Thomas METZMAKER
Abstract: A wearable drug delivery device and method for optimizing performance thereof are provided. A system may include a processor operable with memory, and a drug delivery device and sensor coupled to a user, the sensor operable to detect characteristics of the delivery device. A receiver operable on the processor receives an input signal from the sensor, the input signal representing the detected characteristics. A controller operable on the processor receives the input signal from the receiver, and retrieves, from memory, a baseline characteristics. The controller may determine a location of the delivery device and a tissue profile of the injection location based on a comparison between the detected characteristics and the baseline characteristics. The controller may further control or modify delivery of a liquid drug from the delivery device in response to the location of the delivery device.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.015 seconds)
